Study of DC50292A for advanced solid tumors with MTAP deletion
Part of Cancer clinical trials.
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that is advanced or has spread, and standard treatments have stopped working.
- Your tumor must be MTAP-deficient, meaning it has a specific missing gene (MTAP).
- You must be at least 18 years old.
- You must have at least one tumor that can be measured on scans.
- You need to be in good enough health to carry out daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests an investigational drug called AZD3470, which blocks a protein called PRMT5, in people whose tumors lack a gene called MTAP. The goal is to see if the drug can shrink tumors or slow their growth.
This early-stage trial tests a new drug called HS-10587 in patients whose advanced cancers have a specific genetic feature (MTAP deletion) and have not responded to standard treatments. The drug may help slow or stop cancer growth.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.